S 2695 – MassachusettsStatus: Inactive / Dead
Year Introduced: 2021
Proposes to amend language relative to pharmaceutical access, costs and transparency.
Proposes pharmaceutical manufacturers to have an early notification requirement for pipeline drugs, generic drugs, or biosimilar drugs. Failure to provide an early notification may impose appropriate sanctions against the manufacturer, including reasonable monetary penalties not to exceed $500,000, in each instance. Proposes the commission shall conduct a review of eligible drugs, which may involve requiring a disclosure from the manufacturer regarding pricing.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
No items found